BACKGROUND: Effects were compared in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial of 2 mechanistically different strategies for treatment of hyperglycemia, insulin-sensitizing and insulin-providing strategies, on biomarker profiles reflecting the balance between fibrinolysis and thrombosis and the intensity of inflammation implicated in diabetic vasculopathy. METHODS AND RESULTS: A total of 2368 patients with type 2 diabetes mellitus and clinically stable, angiographically documented coronary artery disease were randomized to treatment with 1 of the 2 strategies and followed for an average of 5 years. Plasminogen activator inhibitor type 1 antigen and activity, tissue plasminogen activator antigen, fibrinogen, D-dimer, C-reactive protein, insulin, and hemoglobin A(1c) were assayed in blood samples acquired at baseline and at 12 regular intervals throughout the follow-up interval. Higher baseline D-dimer, fibrinogen, and C-reactive protein portended a poor prognosis in patients in both groups. In contrast to the insulin-providing strategy, the insulin-sensitizing strategy led to (1) lower plasma insulin; (2) lower plasminogen activator inhibitor type 1 antigen and activity and lower tissue plasminogen activator antigen (known to track with plasminogen activator inhibitor type 1); and (3) lower C-reactive protein and fibrinogen at all intervals after baseline (P<0.001 for each). CONCLUSIONS: The insulin-sensitizing treatment strategy led to changes in biomarker profiles indicative of decreased insulin resistance, an altered balance between thrombosis and fibrinolysis favoring fibrinolysis, and diminished intensity of the systemic inflammatory state, factors that have been associated with cardiovascular risk. CLINICAL TRIAL REGISTRATION: http://www.clinicaltrials.gov. Unique identifier: NCT00006305.
RCT Entities:
BACKGROUND: Effects were compared in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial of 2 mechanistically different strategies for treatment of hyperglycemia, insulin-sensitizing and insulin-providing strategies, on biomarker profiles reflecting the balance between fibrinolysis and thrombosis and the intensity of inflammation implicated in diabetic vasculopathy. METHODS AND RESULTS: A total of 2368 patients with type 2 diabetes mellitus and clinically stable, angiographically documented coronary artery disease were randomized to treatment with 1 of the 2 strategies and followed for an average of 5 years. Plasminogen activator inhibitor type 1 antigen and activity, tissue plasminogen activator antigen, fibrinogen, D-dimer, C-reactive protein, insulin, and hemoglobin A(1c) were assayed in blood samples acquired at baseline and at 12 regular intervals throughout the follow-up interval. Higher baseline D-dimer, fibrinogen, and C-reactive protein portended a poor prognosis in patients in both groups. In contrast to the insulin-providing strategy, the insulin-sensitizing strategy led to (1) lower plasma insulin; (2) lower plasminogen activator inhibitor type 1 antigen and activity and lower tissue plasminogen activator antigen (known to track with plasminogen activator inhibitor type 1); and (3) lower C-reactive protein and fibrinogen at all intervals after baseline (P<0.001 for each). CONCLUSIONS: The insulin-sensitizing treatment strategy led to changes in biomarker profiles indicative of decreased insulin resistance, an altered balance between thrombosis and fibrinolysis favoring fibrinolysis, and diminished intensity of the systemic inflammatory state, factors that have been associated with cardiovascular risk. CLINICAL TRIAL REGISTRATION: http://www.clinicaltrials.gov. Unique identifier: NCT00006305.
Authors: A G Tabák; M Kivimäki; E J Brunner; G D Lowe; M Jokela; T N Akbaraly; A Singh-Manoux; J E Ferrie; D R Witte Journal: Eur J Endocrinol Date: 2010-07 Impact factor: 6.664
Authors: Phyllis August; Regina M Hardison; Fadi G Hage; Oscar C Marroquin; Janet B McGill; Yves Rosenberg; Michael Steffes; Barry M Wall; Mark Molitch Journal: Clin J Am Soc Nephrol Date: 2013-10-31 Impact factor: 8.237
Authors: Saul M Genuth; Helen Vlachos; Maria Mori Brooks; John P Bantle; Bernard R Chaitman; Jennifer Green; Sheryl F Kelsey; Spencer B King; Robert McBane; Edward Y Sako; David J Schneider; Michael Steffes; Robert L Frye Journal: Mayo Clin Proc Date: 2019-10-04 Impact factor: 7.616
Authors: Rozalina G McCoy; Brian A Irving; Mattias Soop; Manivanan Srinivasan; Laura Tatpati; Lisa Chow; Audrey J Weymiller; Rickey E Carter; K Sreekumaran Nair Journal: Mayo Clin Proc Date: 2012-06 Impact factor: 7.616
Authors: Faramarz Ismail-Beigi; Manuel S Lombardero; Jorge Escobedo; Saul Genuth; Jennifer Green; Elaine Massaro; Arshag D Mooradian; Fernando Ovalle; Fred Whitehouse; Joel Zonszein Journal: J Diabetes Complications Date: 2013-03-07 Impact factor: 2.852
Authors: Ran Meng; Xiaoying Wang; Mohammed Hussain; David Dornbos; Lu Meng; Yu Liu; Yan Wu; Mingming Ning; Buonanno Ferdinando S; Eng H Lo; Yuchuan Ding; Xunming Ji Journal: Int J Stroke Date: 2013-03-19 Impact factor: 5.266
Authors: Danny J Eapen; Pankaj Manocha; Riyaz S Patel; Muhammad Hammadah; Emir Veledar; Christina Wassel; Ravi A Nanjundappa; Sergey Sikora; Dylan Malayter; Peter W F Wilson; Laurence Sperling; Arshed A Quyyumi; Stephen E Epstein Journal: J Am Coll Cardiol Date: 2013-05-09 Impact factor: 24.094
Authors: Robert Wolk; Marnie Bertolet; Maria M Brooks; Richard E Pratley; Burton E Sobel; Robert L Frye; Prachi Singh; Andrew D Calvin; Martin K Rutter; Arshag D Mooradian; Virend K Somers Journal: Eur J Prev Cardiol Date: 2014-07-29 Impact factor: 7.804